Furthermore, our results provide mechanistic evidence suggesting that genistein may be utilised as a preventive measure against the inflammation-induced rise in SGLT1 and TMPRSS2, potentially aiding in lowering postprandial glycaemic response and COVID-19 pathophysiology. The gene discussed is SLC5A1; the disease is COVID-19.